BioGend Therapeutics Co., Ltd.

BioGend Therapeutics Co., Ltd. researches, develops, and sells orthopedic medical devices and related products. Its offerings include RevoCart, an autologous cartilage repair system, and SoufCut, an autologous adipose tissue collection system. It is developing BiG-001, an osteoinductive bone graft substitute; BiG-006 for lumbar interbody fusion; and BiG-009, an autologous cartilage repair system for articular cartilage. The company operates in Taiwan, Hong Kong, Chinese Mainland, and Malaysia, and was founded in 2016 with headquarters in Taipei, Taiwan.